Neurologiske bivirkninger af cancerimmunterapi med checkpointinhibitorer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Neurologiske bivirkninger af cancerimmunterapi med checkpointinhibitorer. / Stenör, Christian; Ellebæk, Eva; El Mahdaoui, Sahla; Svane, Inge Marie.

In: Ugeskrift for Laeger, Vol. 183, No. 2, V05200406, 11.01.2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Stenör, C, Ellebæk, E, El Mahdaoui, S & Svane, IM 2021, 'Neurologiske bivirkninger af cancerimmunterapi med checkpointinhibitorer', Ugeskrift for Laeger, vol. 183, no. 2, V05200406. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-01/v05200406_web.pdf>

APA

Stenör, C., Ellebæk, E., El Mahdaoui, S., & Svane, I. M. (2021). Neurologiske bivirkninger af cancerimmunterapi med checkpointinhibitorer. Ugeskrift for Laeger, 183(2), [V05200406]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-01/v05200406_web.pdf

Vancouver

Stenör C, Ellebæk E, El Mahdaoui S, Svane IM. Neurologiske bivirkninger af cancerimmunterapi med checkpointinhibitorer. Ugeskrift for Laeger. 2021 Jan 11;183(2). V05200406.

Author

Stenör, Christian ; Ellebæk, Eva ; El Mahdaoui, Sahla ; Svane, Inge Marie. / Neurologiske bivirkninger af cancerimmunterapi med checkpointinhibitorer. In: Ugeskrift for Laeger. 2021 ; Vol. 183, No. 2.

Bibtex

@article{ab3f2fce762e42a79dd91cd51b5ef666,
title = "Neurologiske bivirkninger af cancerimmunterapi med checkpointinhibitorer",
abstract = "Treatment with checkpoint inhibitors has revolutionised the treatment of many different cancers with a significant improvement in cancer survival. However, a different type of adverse effects is seen compared to standard chemotherapy called immune-related adverse effects (irAE). In this review, we give recommendations on how to diagnose and treat the most common and severe neurologic irAE. We advise clinicians to be cautious to classify neurologic irAE as well-known nosologic entities, since their presentation, cause and treatment often is different.",
keywords = "Drug-Related Side Effects and Adverse Reactions, Humans, Immunotherapy/adverse effects, Neoplasms/drug therapy",
author = "Christian Sten{\"o}r and Eva Elleb{\ae}k and {El Mahdaoui}, Sahla and Svane, {Inge Marie}",
year = "2021",
month = jan,
day = "11",
language = "Dansk",
volume = "183",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "2",

}

RIS

TY - JOUR

T1 - Neurologiske bivirkninger af cancerimmunterapi med checkpointinhibitorer

AU - Stenör, Christian

AU - Ellebæk, Eva

AU - El Mahdaoui, Sahla

AU - Svane, Inge Marie

PY - 2021/1/11

Y1 - 2021/1/11

N2 - Treatment with checkpoint inhibitors has revolutionised the treatment of many different cancers with a significant improvement in cancer survival. However, a different type of adverse effects is seen compared to standard chemotherapy called immune-related adverse effects (irAE). In this review, we give recommendations on how to diagnose and treat the most common and severe neurologic irAE. We advise clinicians to be cautious to classify neurologic irAE as well-known nosologic entities, since their presentation, cause and treatment often is different.

AB - Treatment with checkpoint inhibitors has revolutionised the treatment of many different cancers with a significant improvement in cancer survival. However, a different type of adverse effects is seen compared to standard chemotherapy called immune-related adverse effects (irAE). In this review, we give recommendations on how to diagnose and treat the most common and severe neurologic irAE. We advise clinicians to be cautious to classify neurologic irAE as well-known nosologic entities, since their presentation, cause and treatment often is different.

KW - Drug-Related Side Effects and Adverse Reactions

KW - Humans

KW - Immunotherapy/adverse effects

KW - Neoplasms/drug therapy

M3 - Tidsskriftartikel

C2 - 33491637

VL - 183

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 2

M1 - V05200406

ER -

ID: 288283903